News | September 26, 2023
Biosergen, Alkem collaborate to develop anti-infective for severe fungal infections
Biosergen AB is developing BSG005 for the treatment of severe and difficult-to-treat invasive fungal diseases
Biosergen AB is developing BSG005 for the treatment of severe and difficult-to-treat invasive fungal diseases
Will continue to own a 7.84 per cent stake in Glenmark Life Sciences with the stake reduction
InvaGen has received 5 inspectional observations in Form 483
Norepinephrine Bitartrate Injection is used for restoration of blood pressure in adult patients
Approval is for use in myelofibrosis patients with anaemia regardless of prior myelofibrosis therapy
Opinion granted based on positive disease-free survival results from the Phase 3 KEYNOTE-091 trial
The approval is for acquisition of up to 76.1% equity shares of Suven Pharmaceuticals by Berhyanda Limited
The company has received the Establishment Inspection Report (EIR) from the USFDA for the Pre-Approval Inspection (PAI) at a manufacturing site situated at Savli, Vadodara, Gujarat, with Zero 483 observations
In 2030 over 50% of FDA approvals will involve AI discovered and developed drugs
Biocon Biologics recently acquired the global biosimilars business of its long-term partner Viatris
Subscribe To Our Newsletter & Stay Updated
